Barinthus Bio Provides a Financial Update and Announces Anticipated 2024 Corporate Milestones
05 janv. 2024 16h01 HE
|
Barinthus Biotherapeutics
Barinthus Bio Provides a Financial Update and Announces Anticipated 2024 Corporate Milestones
First Light Acquisition Group, Inc. Announces Effectiveness of Registration Statement and Sets August 22, 2023 as Date of Stockholder Meeting for the Calidi Business Combination
07 août 2023 05h00 HE
|
First Light Acquisition Group
RESTON, Va., Aug. 07, 2023 (GLOBE NEWSWIRE) -- First Light Acquisition Group, Inc. (“FLAG”) (NYSE American: FLAG), a special purpose acquisition company, today announced that the U.S. Securities and...
KAIST and Checkmate Capital Complete Investment in Bredis Healthcare
25 mai 2023 18h00 HE
|
Checkmate Capital
Investment Accelerates Bredis’ Capacity Expansion, Integrated Platform Development and Commercialization in Korea Further Announcement of Bredis’ Agreements with Major University Hospitals SEOUL,...
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
08 déc. 2022 16h10 HE
|
Inotiv, Inc.
WEST LAFAYETTE, Ind., Dec. 08, 2022 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and...
Endure Biotherapeutics, Inc. Announces Publication of Founder’s Seminal Work Regarding Colonizing Biotherapeutics
15 août 2022 23h41 HE
|
Endure Biotherapeutics, Inc.
San Diego, Aug. 15, 2022 (GLOBE NEWSWIRE) -- FOR IMMEDIATE RELEASE Endure Biotherapeutics, Inc. Announces Publication of Founder’s Seminal Work Regarding Colonizing Biotherapeutics Zarrinpar...
NeuroSigma Announces King’s College London Team Receives MHRA Approval to Commence Largest Clinical Trial of eTNS for Pediatric ADHD to Date
07 avr. 2022 11h00 HE
|
NeuroSigma, Inc.
Double-blind randomized controlled trial of eTNS for pediatric ADHD will enroll up to 150 participants at two sites in London and Southampton NeuroSigma’s Monarch eTNS System and electric patches to...
Progenity Announces Oral Presentation on Treatment of Gastrointestinal Disorders at 34th Belgian Week of Gastroenterology
11 janv. 2022 06h30 HE
|
Progenity, Inc.
SAN DIEGO, Jan. 11, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company innovating in the field of oral biotherapeutics for gastrointestinal health and beyond, today...
Progenity Announces Acceptance of Two Abstracts on Treatment of Gastrointestinal Disorders at ECCO’22
05 janv. 2022 06h30 HE
|
Progenity, Inc.
SAN DIEGO, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company innovating in the field of oral biotherapeutics for gastrointestinal health and beyond, today...
Inotiv, Inc. and Synexa Life Sciences Sign Letter of Intent to Establish Center of Excellence for Biotherapeutics and Biomarkers
04 janv. 2022 08h33 HE
|
Inotiv, Inc.
-- Expected to establish a leading global provider of full-spectrum, preclinical and clinical biotherapeutics and biomarker analysis solutions -- -- Expected to enhance scale, broaden customer base...
Progenity to Participate in the H.C. Wainwright BIOCONNECT Virtual Conference
03 janv. 2022 06h30 HE
|
Progenity, Inc.
SAN DIEGO, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company innovating in the field of oral biotherapeutics for gastrointestinal health and beyond, today...